XBiotech Inc. (NASDAQ:XBIT - Get Free Report)'s stock price passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $2.94 and traded as low as $2.57. XBiotech shares last traded at $2.64, with a volume of 73,201 shares changing hands.
XBiotech Trading Down 4.7%
The firm has a market capitalization of $79.58 million, a price-to-earnings ratio of -2.02 and a beta of 0.97. The stock's fifty day moving average price is $2.92 and its two-hundred day moving average price is $3.63.
XBiotech (NASDAQ:XBIT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its holdings in XBiotech by 68.2% in the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 5,930 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of XBiotech during the 4th quarter worth approximately $58,000. Hsbc Holdings PLC purchased a new stake in shares of XBiotech during the 1st quarter worth approximately $52,000. Bank of America Corp DE boosted its holdings in shares of XBiotech by 42.0% in the 4th quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock valued at $79,000 after buying an additional 5,887 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of XBiotech in the 1st quarter valued at $81,000. Hedge funds and other institutional investors own 55.70% of the company's stock.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Featured Articles
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
